Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan
Telmisartan/Hydrochlorothiazide
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- History of mild-to-moderate hypertension
- Patients who fail to respond adequately to telmisartan monotherapy
- Participants between 18 and 80 years of age
- Ability to provide written informed consent
Exclusion Criteria:
- Patients taking more than three anti-hypertensive medications at the screening visit
Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening)
- Who are not surgically sterile (hysterectomy, tubal ligation)
- Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study
Any women:
- Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4)
- Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
- Serum creatinine > 2.3 mg/dL
- Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
- Known or suspected secondary hypertension
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
- Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
- Unstable angina within the past three months
- Stroke within the past six months
- Myocardial infarction or cardiac surgery within the past three months
- PTCA (percutaneous transluminal coronary angioplasty) within the past three months
- History of angioedema
- Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
- Administration of digoxin or other digitalis-type drugs
- Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
- Known drug or alcohol dependency within the past one year period
- Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
- Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
- Known hypersensitivity to any component of the formulations
- Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Telmisartan plus Hydrochlorothiazide
Telmisartan
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in seated diastolic blood pressure (DBP) at trough
Secondary Outcome Measures
Change from baseline in seated systolic blood pressure (SBP) at trough
Change from baseline in standing DBP and SBP at trough
Blood pressure control (seated DBP < 90 mmHg)
Systolic blood pressure response
Number of patients with abnormal findings in physical examination
Changes from baseline in heart rate
Number of patients with abnormal changes in laboratory parameters
Number of patients with abnormal changes in resting 12-lead ECG (electrocardiogram)
Orthostatic changes in blood pressure
Number of patients with adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02177435
Brief Title
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
Official Title
An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
February 1999 (undefined)
Primary Completion Date
September 1999 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Study to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (FDC 80/12.5) is superior to telmisartan 80 mg (Telm 80) alone in patients who failed to respond adequately to Telm 80 monotherapy in lowering seated trough diastolic blood pressure (DBP) after eight weeks of treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
491 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Telmisartan plus Hydrochlorothiazide
Arm Type
Experimental
Arm Title
Telmisartan
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Telmisartan/Hydrochlorothiazide
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in seated diastolic blood pressure (DBP) at trough
Time Frame
Baseline (day 0), day 28, day 56
Secondary Outcome Measure Information:
Title
Change from baseline in seated systolic blood pressure (SBP) at trough
Time Frame
Baseline (day 0), day 28, day 56
Title
Change from baseline in standing DBP and SBP at trough
Time Frame
Baseline (day 0), day 28, day 56
Title
Blood pressure control (seated DBP < 90 mmHg)
Time Frame
16 weeks
Title
Systolic blood pressure response
Time Frame
16 weeks
Title
Number of patients with abnormal findings in physical examination
Time Frame
Baseline (screening), day 0 and day 56
Title
Changes from baseline in heart rate
Time Frame
Baseline (screening), day -56, -28, 0, 28 and 56
Title
Number of patients with abnormal changes in laboratory parameters
Time Frame
Baseline (screening), day 0 and day 56
Title
Number of patients with abnormal changes in resting 12-lead ECG (electrocardiogram)
Time Frame
Baseline (screening), day 0 and day 56
Title
Orthostatic changes in blood pressure
Time Frame
Baseline (screening), day -56, -28, 0, 28 and 56
Title
Number of patients with adverse events
Time Frame
up to 16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of mild-to-moderate hypertension
Patients who fail to respond adequately to telmisartan monotherapy
Participants between 18 and 80 years of age
Ability to provide written informed consent
Exclusion Criteria:
Patients taking more than three anti-hypertensive medications at the screening visit
Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening)
Who are not surgically sterile (hysterectomy, tubal ligation)
Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study
Any women:
Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4)
Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
Serum creatinine > 2.3 mg/dL
Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
Known or suspected secondary hypertension
Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
Unstable angina within the past three months
Stroke within the past six months
Myocardial infarction or cardiac surgery within the past three months
PTCA (percutaneous transluminal coronary angioplasty) within the past three months
History of angioedema
Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
Administration of digoxin or other digitalis-type drugs
Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
Known drug or alcohol dependency within the past one year period
Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
Known hypersensitivity to any component of the formulations
Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.261_U00-3112.pdf
Description
Related Info
Learn more about this trial
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
We'll reach out to this number within 24 hrs